Inhibitors of PD-1/PD-L1 and ERK1/2 Impede the Proliferation of Receptor Positive and Triple-Negative Breast Cancer Cell Lines

The effect of combined PD-1/PD-L1 and extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor treatment was investigated of cell growth and intracellular impact of breast cancer cell lines.